ARCA Biopharma
$28.8
42
+$26.3+1,052% Friday 20:00
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Dividends
0%Dividend Yield
Aug 24
$1.61
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A
Earnings
6NovExpected
Expected EPS
N/A
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-5.34MNet Income
Analyst Ratings
78.9Average Price Target
The highest estimate is 125.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ABIO. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap191.53B
Pfizer
PFE
Mkt Cap156.77B
Novartis
NVS
Mkt Cap293.34B
Merck
MRK
Mkt Cap294.39B
Bristol-Myers Squibb
BMY
Mkt Cap122.85B
Gilead Sciences
GILD
Mkt Cap170.84B
Abbvie
ABBV
Mkt Cap368.57B
Astrazeneca
AZN
Mkt Cap317.5B
Johnson & Johnson
JNJ
Mkt Cap564.35B
Sanofi
SNY
Mkt Cap115.14B
About
Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Show more...
CEO
Michael Bristow
Employees
3
Country
United States
ISIN
US00211Y5069
Listings
0 Comments
Share your thoughts
FAQ
What is ARCA Biopharma stock price today?▼
The current price of ABIO is $28.8 USD — it has increased by +1,052% in the past 24 hours. Watch ARCA Biopharma stock price performance more closely on the chart.
What is ARCA Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange ARCA Biopharma stocks are traded under the ticker ABIO.
What is ARCA Biopharma revenue for the last year?▼
ARCA Biopharma revenue for the last year amounts to 0 USD.
What is ARCA Biopharma net income for the last year?▼
ABIO net income for the last year is -5.34M USD.
Does ARCA Biopharma pay dividends?▼
Yes, ABIO dividends are paid en. The last dividend per share was 1.61 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does ARCA Biopharma have?▼
As of April 21, 2026, the company has 3 employees.
In which sector is ARCA Biopharma located?▼
ARCA Biopharma operates in the Technology sector.
When did ARCA Biopharma complete a stock split?▼
The last stock split for ARCA Biopharma was on April 04, 2019 with a ratio of 1:18.
Where is ARCA Biopharma headquartered?▼
ARCA Biopharma is headquartered in Westminster, United States.